Objective:To observe effects of Sindilumab combined with TP chemotherapy in treatment of patients with advanced esophageal cancer.Methods:A prospective study was conducted on 100 patients with advanced esophageal cancer admitted to this hospital from 2020 to 2022.According to the random number table method,they were divided into study group and control group,50 cases in each group.The control group was treated with TP chemotherapy regimen,while the study group was treated with Sindilumab on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)]before and after the treatment,the quality of life[Karnofsky functional status(KPS)]score,the 1-year survival rate,and the incidence of adverse reactions were compared between the two groups.Results:The objective response rate(ORR)of the study group was 84.21%(43/50),which was higher than 63.16%(31/50)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of VEGF,CEA and NSE in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The KPS score and the 1-year survival rate of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sindilimab combined with TP chemotherapy in the treatment of the patients with advanced esophageal cancer can improve the ORR,the KPS scores and the 1-year survival rate,and reduce the levels of tumor markers.Moreover,it is superior to simple TP chemotherapy treatment.
关键词
信迪利单抗/TP化疗方案/中晚期/食管癌/生存质量/肿瘤标志物/不良反应
Key words
Sindilumab/TP chemotherapy regimen/Advanced/Esophageal cancer/Quality of life/Tumor marker/Adverse reaction
维普
万方数据